+ ) were present in large numbers at the tumor site and in the spleen of tumor-bearing type I NKT-deficient mice, suggesting that antitumor immunosurveillance was inhibited by CD11b + Gr1 + cells. Overall, these data suggest that there are distinct roles for NKT cell subsets in response to a B cell lymphoma in vivo, pointing to potential novel targets to be exploited in immunotherapeutic approaches against blood cancers.
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Introduction
Tumors must escape from the host's immune surveillance in order to survive and grow.
Lymphoma is a general term for cancers that develop in the lymphatic system and it is the third most common cancer in children and adolescents 1 . To improve the outcome in patients with hematopoietic tumors, a better understanding of the immunobiology of lymphoma is essential. A novel lymphocyte population which has been identified as a key player in both innate and acquired immune responses, including as antitumor effector cells, is the natural killer T (NKT) cell [2] [3] [4] . NKT cells recognize lipid antigens presented by the MHC class I-like CD1d molecule and express cell surface markers shared with NK cells 3 . The vast majority of these T cells are canonical or invariant NKT (type I NKT) cells that possess a specific TCR α-chain rearrangement (Vα14Jα18 in mice; Vα24Jα18 in humans), associated with Vβ chains of limited diversity. All other NKT cells which are CD1d-restricted, and do not express this invariant TCR are called type II NKT cells 5, 6 . Unlike type I NKT cells, little is known about type II NKT cells, but there is some evidence that type II NKT cells are a functionally important T cell subset 5 . As CD1d molecules are vital for NKT cell development 7 , mice lacking the CD1d1 gene (CD1KO mice) are deficient in all CD1d-restricted NKT cells (both type I and type II) 8 . Mice lacking the Jα18 gene (Jα18KO mice) is deficient only in type I NKT cells. As NKT cells are capable of secreting both Th1 and Th2 cytokines, this has made it difficult to predict the consequences of their activation in vivo but has nonetheless created much speculation that they play a central role in immunoregulation 2 .
For personal use only. on October 23, 2017 . by guest www.bloodjournal.org From NKT cells are directly cytotoxic and their activation can also result in "adjuvant effects" during antitumor immune responses by activating other cytotoxic lymphocytes, mainly through a Th1 cytokine cascade 4 . However, there are reports demonstrating a suppressive antitumor role for CD4 + NKT cells in some murine tumor models 9 , and type II NKT cells were shown to be capable of down-regulating tumor immunosurveillance 10 .
The role of NKT cells in the evasion of hematopoietic tumors from the host's innate antitumor immune response in vivo has only recently begun to be investigated, and we have reported that type I NKT cells play an inhibitory role in a murine T cell lymphoma model 11 . Several human hematopoietic cell types express CD1d on their surface 12 
Materials and Methods
Mice. Inbred BALB/c wildtype mice were obtained from The Jackson Laboratory (Bar Harbor, ME). CD1d1-deficient (CD1KO) mice 8 were obtained from L. Van Kaer (Vanderbilt University, Nashville, TN). Jα18KO mice 18 were kindly provided by Dr. R.
Singh (University of Cincinnati, Cincinnati, OH) with permission from Dr. M. Taniguchi (Chiba University, Japan). All gene-targeted mice were backcrossed onto the BALB/c background for 10 generations. All mice were age-and sex-matched and used between 6 and 12 weeks of age. All animal procedures were approved by the Indiana University
School of Medicine Institutional Animal Care and Use Committee.
Antibodies. The mouse CD1d-specific 1H6 mAb has been previously described 19 . 1H6
ascites and the isotype control mAb HB158 hybridoma supernatant were purified on a protein A column for in vivo use. PE-or FITC-conjugated antibodies specific for mouse CD4, CD8, TCRβ, B220, Gr-1, CD11b, CD44, and DX5 were purchased from BDPharMingen (San Diego, CA). PE-conjugated rabbit anti-mouse Ig antiserum was purchased from Dako (Carpinteria, CA). Purified and biotinylated antibodies specific for mouse TGFβ and IL-13  were purchased from R&D Systems (Minneapolis, MN), whereas those specific for mouse IL-2, IL-12, IFN-γ , and GM-CSF were purchased from BD-PharMingen (San Diego, CA). All the cytokine standards used in the ELISA assays were purchased from PeproTech (Rocky Hill, NJ).
Tumor cell lines and murine type I NKT cells. The B cell lymphoma cell line NS0 was kindly provided by S. Joyce (Vanderbilt University, Nashville, TN). NS0 cells were harvested from NS0-V-or NS0-CD1-bearing mice for FACS analyses of the MDSC population was performed as previously described 11 . The murine NKT cell hybridoma assay was performed as described 19 . Briefly, NS0-V-or NS0-CD1 cells were cocultured with murine NKT cell hybridoma DN32.D3 22, 23 Figure 2A ). Less than 30% of the wildtype and CD1KO mice succumbed to either tumor; these mice suffered less and survived longer as compared to Jα18KO mice ( Figure 2A and Table 1 , and these two lymphocyte populations 19 or an isotype control mAb. It was found that the 1H6 mAb completely restored the level of survival in tumor-bearing Jα18KO mice to that observed in wildtype mice ( Figure 3 ; Table 2 ). Furthermore, 1H6 can substantially impair cytokine production by NKT cells following injection of α-GalCer in vivo (data not shown). These data are supported by an earlier study showing that the in vivo function of NKT cells could be blocked using an anti-CD1d antibody 10 . These results further confirmed a possible suppressive function for type II NKT cells against a B cell lymphoma. The antibody-mediated CD1d block in wildtype mice also did not alter tumor incidence, suggesting that inhibiting both NKT cell subsets has no effect on survival in this tumor model.
Pro-and anti-inflammatory cytokines profile reflects tumor progression
In other murine tumor model systems, it has been reported that CD4 + NKT cells exert an inhibitory effect on antitumor immunosurveillance mediated through the actions of antiinflammatory cytokines like IL-13 9 . Similarly, we have reported in a murine T cell lymphoma model that Jα18KO and CD1KO mice produce lower levels of Th2 cytokines and survive longer than wildtype mice 11 . In the current study, to explore how type I and II NKT cell subsets mediated the divergent antitumor immune response to a B cell 
Discussion
Unlike murine NKT cells, the number of type I NKT cells in humans is highly variable among individuals and they represent only a small portion of total NKT cells, whereas type II NKT cells are the major population [35] [36] [37] [38] [39] [40] . Therefore, it is very essential to delineate the independent roles of NKT cell subsets in antitumor immunity in order to design effective immunotherapeutic strategies. Our previous studies have identified a suppressive antitumor immune response mediated by type I NKT cells in a murine T cell lymphoma model 11 (Fig. 1A) , and the well-known inverse correlation between MHC class I levels and susceptibility to lysis by NK cells 29 , this result may not be that surprising.
Recently, it has been demonstrated that interactions between type II NKT cells and hepatic DCs result in the regulation of type I NKT cell activity in Concanavalin Ainduced hepatitis 47 ; it is important to note that BALB/c mice are mainly Th2 cytokine- .
Were cross-presentation to be the major mechanism operative in our NS0 system, we would expect there to be a comparable reduction in NS0-V and NS0-CD1 tumor growth in Jα18KO mice receiving type I NKT cells (dendritic cells in these animals are CD1d + ).
As there was only a decrease in NS0-CD1 tumor growth upon the adoptive transfer of The P values are based on the Log-rank test comparing either two groups of mice with one cell line or two cell lines with one group of mice as indicated. The P values are based on the Log-rank test comparing either two groups of mice with one cell line or two cell lines with one group of mice as indicated. 
